logo
logo

Trialjectory Raises $20 Million To Transform The Cancer Care Industry

Feb 07, 2022•over 3 years ago

Amount Raised

$20 Million

Description

Trialjectory ("the Company"), the AI-powered decision-support platform for patients, health-care providers and pharma, announced today that it has raised $20 million in a Series A round led by New York-based global private equity and venture capital firm Insight Partners, with participation from new investor JAL Ventures and from existing investors Contour Venture Partners, Rho Capital and TIA Ventures. Trialjectory will use the funding to transform cancer care by defining a new market category focused on delivering personalized, treatment decision-support and a new way for pharma to offer an authentic, patient-centered experience.

Company Information

Company

Trialjectory

About

Trialjectory is an artificial intelligence (AI)-powered decision-support platform democratizing access to advanced cancer treatments. Using AI technology, Trialjectory addresses multiple challenges facing the oncology drug development ecosystem. Its unique model informs and empowers cancer patients to own their treatment journey, supports a more personalized approach to patient-care and helps pharma achieve patient-centered, drug development. Award winning offering: Trialjectory has been recognized by TIME as one of "The 100 Best Inventions of 2020" and named an honoree in the AI and data category for Fast Company's "2021 World Changing Ideas Awards," For more information, please visit www.trialjectory.com, and follow the Company on Facebook and LinkedIn

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech